INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer Interface Technology - Capital-Riesgo.es
Summary
INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced the close of a $50 million Series B financing round. This partnership will boost the translation of INBRAINs platform to human use, expanding its impact across both central and peripheral nervous system applications.The companys technology utilizes the unique properties of graphene, a Nobel Prize-winning material known for its strength, flexibility, and conductivity. The funding will support ongoing clinical trials, enable team expansion and further develop the companys AI-powered platform for the treatment of neurological-related diseases.Were shaping the future of brain-computer interface therapeutics, said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. By harnessing the remarkable properties of graphene, INBRAIN is advancing cutting-edge neurotechnology applications that could significantly improve patient outcomes and also position Europe as one of the leaders in the global BCI industry. With this important investment, we are proud to support INBRAIN in translating this technology from research into real-world impact on patients lives.INBRAIN Neuroelectronics is pioneering real-time precision neurology with the worlds first graphene-based brain-computer interface therapeutics (BCI-Tx) platform.